Answers are grounded in this paper and cite their sources.
INTRODUCTION: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid β (Aβ) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD. No significant gender differences were observed. DISCUSSION: , P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available.
No takes yet. Share an insight, caveat, or question.
Hamlett et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: